<p>思路迪医药股份：</p>
<ul>
<li>ENVAFOIMAB 获得孤儿药资格</li>
<li>中国国家药品监督管理局授予胃癌和胃食管交界癌适应症的资格</li>
</ul>

思路迪医药股份

<p>3D MEDICINES：ENVAFOIMAB 获得中国 NMPA 授予的用于治疗胃癌和胃食管交界癌的孤儿药资格</p>

<p>3D Medicines Inc :</p>
<div class="lb-trans"><p>思路迪医药股份：</p>
</div><ul>
<li>ENVAFOIMAB GRANTED ORPHAN DRUG DESIGNATION</li>
<li>DESIGNATION FOR TREATMENT OF GASTRIC CANCER AND - GASTRO-ESOPHAGEAL JUNCTION CANCER INDICATIONS BY CHINA NMPA</li>
</ul>
<div class="lb-trans"><ul>
<li>ENVAFOIMAB 获得孤儿药资格</li>
<li>中国国家药品监督管理局授予胃癌和胃食管交界癌适应症的资格</li>
</ul>
</div>

3D MEDICINES 表示，Envafoimab 已被授予孤儿药资格认定